Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

APOE Antikörper

Dieses Maus Monoklonal-Antikörper erkennt spezifisch APOE in ELISA, IHC und FACS. Er zeigt eine Reaktivität gegenüber Human und wurde in 2+ Publikationen erwähnt.
Produktnummer ABIN968962

Kurzübersicht für APOE Antikörper (ABIN968962)

Target

Alle APOE Antikörper anzeigen
APOE (Apolipoprotein E (APOE))

Reaktivität

  • 110
  • 86
  • 74
  • 4
  • 4
  • 2
  • 2
  • 1
  • 1
  • 1
Human

Wirt

  • 124
  • 45
  • 9
  • 2
  • 1
Maus

Klonalität

  • 122
  • 58
Monoklonal

Konjugat

  • 97
  • 18
  • 11
  • 6
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
Dieser APOE Antikörper ist unkonjugiert

Applikation

  • 146
  • 68
  • 60
  • 47
  • 44
  • 39
  • 39
  • 22
  • 13
  • 12
  • 8
  • 6
  • 5
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Klon

1H4
  • Verwendungszweck

    ApoE Antibody

    Aufreinigung

    Ascitic fluid

    Immunogen

    Purified recombinant fragment of human ApoE expressed in E. Coli.

    Isotyp

    IgG1
  • Applikationshinweise

    ELISA: 1/10000

    FCM: 1/200 - 1/400

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Buffer

    Ascitic fluid containing 0.03 % sodium azide.

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
  • Karpouzis, Caridha, Tripsianis, Michailidis, Martinis, Veletza: "Apolipoprotein E gene polymorphism in psoriasis." in: Archives of dermatological research, Vol. 301, Issue 6, pp. 405-10, (2009) (PubMed).

    Zintzaras, Kitsios, Triposkiadis, Lau, Raman: "APOE gene polymorphisms and response to statin therapy." in: The pharmacogenomics journal, Vol. 9, Issue 4, pp. 248-57, (2009) (PubMed).

  • Target

    APOE (Apolipoprotein E (APOE))

    Andere Bezeichnung

    ApoE

    Hintergrund

    Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20 % of very low density lipoproteins (VLDL) and 1-2 % of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.

    Molekulargewicht

    36 kDa

    Gen-ID

    348

    UniProt

    P02649

    Pathways

    Regulation of Cell Size, Lipid Metabolism
Sie sind hier:
Chat with us!